Pharmafile Logo

Syndesi Therapeutics

- PMLiVE

AbbVie expands Oxford R&D as part of more than £120m investment in UK life sciences

The new site will expand research capabilities across immunology, neuroscience and oncology

- PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

- PMLiVE

Galimedix establishes Alzheimer’s Disease Scientific Advisory Board

The Board will advise Galimedix on scientific and clinical strategy

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Alzheimer’s groups call for urgent global focus on women’s brain health

New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association

- PMLiVE

AbbVie to acquire Apogee Therapeutics in $10.9bn deal

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

- PMLiVE

Allergan Aesthetics launches Skin Quality Index for aesthetic consultations

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions

- PMLiVE

AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment

The agreement covers the development of new lead tau morphomer candidates

- PMLiVE

Eisai and Biogen’s new data shows Alzheimer’s patients choose to stay on Leqembi long-term

The findings were presented at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases in Denmark

- PMLiVE

Eisai and Biogen’s subcutaneous Leqembi given FDA Priority Review for early Alzheimer’s

Administering the drug subcutaneously rather than intravenously showed similar clinical benefits for patients

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links